Press Release November 10, 2020

Apollomics, Inc. Closes $124 Million Series C Financing

The Life Sciences team advised Apollomics, Inc. on its $124.2 million Series C Financing led by Ping An Capital with participation from several new and existing investors.

Apollomics, incubated by OrbiMed Asia at inception, is an innovative biopharmaceutical company committed to the discovery and development of oncology mono- and combination- therapies that harness the immune system and target specific molecular pathways to eradicate cancer.

Proceeds from the Series C financing will support the development of the Apollomics pipeline with a focus on the Company’s lead programs: APL-101 and APL-106.

The Goodwin team was led by Wenseng “Wendy” Pan and included with valuable assistance from Maggie L. Wong, Kimberley Maruncic, Mark H. Burnett, and Jacob R. Osborn.

For more details, read the press release and articles in Endpoints, S&P Global, and Deal Street Asia.